title: Continuous hyperthermic peritoneal perfusion (CHPP) for malignant ascites and irresectable intra-abdominal cancer.
authors.affiliation: Dept. of Surgical Oncology, Chaim Sheba Medical Center, Israel.
authors.forename: G
authors.initials: G
authors.lastname: Ben-Ari
authors.forename: D
authors.initials: D
authors.lastname: Scott
authors.forename: D
authors.initials: D
authors.lastname: Zippel
authors.forename: M
authors.initials: M
authors.lastname: Sareli
authors.forename: M
authors.initials: M
authors.lastname: Koller
authors.forename: M
authors.initials: M
authors.lastname: Papa
mesh_terms: D000008:Abdominal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001201:Ascites / Q000401:mortality / Q000628:therapy*; D002455:Cell Division; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D006979:Hyperthermia, Induced; D007263:Infusions, Parenteral / Q000379:methods; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D010477:Perfusion; D015996:Survival Rate
chemical_list: D016685:Mitomycin; D002945:Cisplatin; D008558:Melphalan; D005472:Fluorouracil